Amarin Corp Plcuk (AMRN) Shares Outstanding (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Shares Outstanding of $419.6 million for Q1 2026, down 1.7% year-over-year from $426.8 million in Q1 2025, and down 2.39% quarter-over-quarter from $429.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Shares Outstanding (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Shares Outstanding data on file, last reported at $419.6 million in Q1 2026.
- Shares Outstanding for Q1 2026 came in at $419.6 million, down 1.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $419.6 million (down 1.7% YoY), and the FY2025 annual result was $429.8 million, up 1.8% from the prior year.
- Shares Outstanding retreated to $419.6 million in Q1 2026 per AMRN's latest filing, from $429.8 million in the prior quarter.
- Over five years, Shares Outstanding peaked at $429.6 million in Q3 2025 and troughed at $404.6 million in Q1 2022.
- A 5-year average of $418.3 million and a median of $418.1 million in 2023 frame the typical range for Shares Outstanding.
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding rose 2.97% in 2023, then retreated 1.7% in 2026.
- A 5-year view of Shares Outstanding shows it stood at $412.3 million in 2022, then climbed by 1.41% to $418.1 million in 2023, then increased by 0.98% to $422.3 million in 2024, then increased by 1.8% to $429.8 million in 2025, then decreased by 2.39% to $419.6 million in 2026.
- Business Quant data shows AMRN's Shares Outstanding at $419.6 million in Q1 2026, $429.8 million in Q4 2025, and $429.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 943.50 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.12 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 3.58 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 539.70 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 9.64 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.92 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 419.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Mar 31, 2026 | 419.59 Mn |
| Dec 31, 2025 | 416.21 Mn |
| Dec 31, 2025 | 429.85 Mn |
| Dec 31, 2025 | 429.85 Mn |
| Dec 31, 2025 | 429.85 Mn |
| Dec 31, 2025 | 416.21 Mn |
| Dec 31, 2025 | 416.21 Mn |
| Dec 31, 2025 | 416.21 Mn |
| Dec 31, 2025 | 429.85 Mn |
| Sep 30, 2025 | 429.60 Mn |
| Sep 30, 2025 | 429.60 Mn |
| Sep 30, 2025 | 429.60 Mn |
| Sep 30, 2025 | 429.60 Mn |